Kinetic profile of carbamazepine in an adult Portuguese outpatient population
A. M. Almeida MSc
Search for more papers by this authorA. C. Falcão PhD
Search for more papers by this authorF. Sales MD
Neurology Department, Coimbra University Hospital, 3000 Coimbra, Portugal
Search for more papers by this authorF. Leitão MD
Laboratory of Hormonology and Therapeutic Drug Monitoring, Coimbra University Hospital, 3000 Coimbra, Portugal
Search for more papers by this authorJ. Santos PharmD
Laboratory of Hormonology and Therapeutic Drug Monitoring, Coimbra University Hospital, 3000 Coimbra, Portugal
Search for more papers by this authorI. M. Costa PharmD
Search for more papers by this authorM. M. Caramona PhD
Search for more papers by this authorA. M. Almeida MSc
Search for more papers by this authorA. C. Falcão PhD
Search for more papers by this authorF. Sales MD
Neurology Department, Coimbra University Hospital, 3000 Coimbra, Portugal
Search for more papers by this authorF. Leitão MD
Laboratory of Hormonology and Therapeutic Drug Monitoring, Coimbra University Hospital, 3000 Coimbra, Portugal
Search for more papers by this authorJ. Santos PharmD
Laboratory of Hormonology and Therapeutic Drug Monitoring, Coimbra University Hospital, 3000 Coimbra, Portugal
Search for more papers by this authorI. M. Costa PharmD
Search for more papers by this authorM. M. Caramona PhD
Search for more papers by this authorAbstract
Objective : The aim of our work was to define the kinetic profile of carbamazepine (CBZ), in order to improve on dosing schedules through a Bayesian approach. Method: Carbamazepine dose/steady-state trough concentrations data pairs and associated information were collected retrospectively on a population of adult epileptic patients. Results: Fifty patients (index population) with two or more available concentrations (total of 174 determinations) met our inclusion criteria. Patients were taking CBZ (200–1800 mg/day) in mono- or polytherapy regimens. The analysis assumed a one-compartimental model with first-order absorption and elimination. Due to the data source (only trough concentrations were measured as part of hospital routine), the volume of distribution was fixed at 1·19 l/kg. The final estimates for CL were: 0·075± 0·027 (mono- and polytherapy), 0·069±0·020 (monotherapy), and 0·106±0·037 l/h/kg (poly?therapy). In order to validate these results, we assessed their predictive capacity using 18 new patients (validation population), submitted to the same inclusion criteria and using Prediction-Error analysis. The results suggested a different CL value for our population compared to earlier published clearance values. The results also pointed to an increased metabolic rate associated with polytherapy. The prediction capacity of the optimization method derived from a Portuguese population made in an a priori evaluation indicated a low error (–0·04 μg/ml), close to the theoretical zero value. Conclusion: Our results provide specific data on CBZ disposition in a Portuguese population and given the wide variability in the literature values, our data may help improve dosing of CBZ in Portuguese patients.
References
- 1 BertilssonL & TomsonT1986Clinical pharmacokinetics and effects of carbamazepine and carbamazepine-10,11-epoxide. An updateClinical Pharmacokinetics 11 177 198
- 2 ThomsonAH & BrodieMJ1992Pharmacokinetic optimization of anticonvulsant therapyClinical Pharmacokinetics 23 216 230
- 3 BaciewiczAM1986Carbamazepine drug interactionsTherapeutic Drug Monitoring 8 305 317
- 4 BrodieMJ1992Drug interaction in epilepsyEpilepsia 33 S13 S22
- 5 SpinaE, PisaniF, PeruccaE1996Clinically significant pharmacokinetic drug interaction with carbamazepineClinical Pharmacokinetics 31 198 214
- 6 RivaR, AlbaniF, ContinM, BaruzziA1996Pharmacokinetic interactions between antiepileptic drugsClinical Pharmacokinetics 31 470 493
- 7 SheinerLB, BealS, RosenbergB, MaratheVV1979Forecasting individual pharmacokineticsClinical Pharmacology Therapeutics 26 294 305
- 8 TanigawaraY, YanoI, KawakatsuK, NishimuraK, YasuharaM, HoriR1994Predictive performance of Bayesian Analysis: effects of blood sampling time, population parameters, and pharmacostatistical modelJournal of Pharmacokinetics and Biopharmaceutics 22 59 71
- 9 El BattahA, BegliaS, AlricR1995Validation of a quick modelling program generating clearance estimates at steady state for routine therapeutic drug monitoringTherapeutic Drug Monitoring 17 348 355
- 10 AlmeidaAM, CanasN, CostaIM, CaramonaMM, FalcãoAC1997PKBase – A database developed for populational pharmacokinetic studies: concept and application [abstract]Therapeutic Drug Monitoring 19 548
- 11 Alonso GonzalezAC, Garcia SanchezMJ, Dominguez-Gil HurleA1988Contribution of serum level monitoring in the individualization of carbamazepine dosage regimensInternational Journal of Clinical Pharmacology Therapy, and Toxicology 26 409 412
- 12 RosnerB1995 Fundamentals of Biostatistics, 4th edn. Duxbury Press, Belmont. p. 34.
- 13 SánchezA, DuránJA, SerranoJS1986Steady-state carbamazepine plasma concentration-dose ratios in epileptic patientsClinical Pharmacokinetics 11 411 414
- 14 LuiH & DelgadoMR1994Influence of sex, age, weight and carbamazepine dose on serum concentrations, concentration ratios, and level/dose ratios of carbamazepine and its metabolitesTherapeutic Drug Monitoring 16 469 476
- 15 BattinoD, EstienneM, AvanziniG1995Clinical Pharmacokinetics of antiepileptic drugs in paediatric patients: Part II. Phenytoin, carbamazepine, sulthiame, lamo?trigine, vigabatrin, oxcarbazepine and felbamateClinical Pharmacokinetics 29 341 369
- 16 BernusI, DickinsonRG, HooperWD, EadieMJ1997Anticonvulsant therapy in aged patientsDrug and Ageing 10 278 289
- 17 BuffingtonDE, LampasonaV, ChandlerMHH1993Computers in pharmacokineticsClinical Pharmaco?kinetics 25 205 216
- 18 Santos BuelgaD, VasquezA, AlonsoAC, GarciaMJ, Dominguez-GilA1990Comparison of two methods in the estimation of the pharmacokinetic parameters of phenytoinJournal of Clinical Pharmacy and Therapeutics 15 225 231
- 19 AlmeidaAM, CostaIM, LeitoF, SantosJ, CaramonaMM, FalcãoAC1997Evaluation of Bayesian prediction of carbamazepine in a Portuguese outpatient population [abstract]Therapeutic Drug Monitoring 19 569
- 20 BenetLZ, OieS, SchwartzJB1995 Design and optimization of dosage regimens; pharmacokinetic data. In: Hardman JG, Linbird LE, Molinoff PB, Ruddon RW, Goodman Gilman A, eds. The Phamacological Basis of Therapeutics. McGraw-Hill, New York, Appendix II.
- 21 SheinerLB & BealSL1981Some suggestions for measuring predictive performanceJournal of Pharmacokinetics and Biopharmamaceutics 9 503 513
- 22 GarciaMJ, AlonsoAC, MazaA, SantosD, MatesanzC, Dominguez-GilH1988Comparison of methods of carbamazepine dosage, individualization in epileptic patientsJournal of Clinical Pharmacy and Therapeutics 13 375 380
- 23 KillileaT, ColemanR, LuddenT, PeckCC, RoseD1989Bayesian regression analysis of non-steady-state phenytoin concentrations: evaluation of predictive performanceTherapeutic Drug Monitoring 11 455 462
- 24 PughCB, GarnettWR, PellockJM1989Usefulness of a single-dose prediction model for the determination of a long-term maintenance therapy of valproic acidTherapeutic Drug Monitoring 11 658 660
- 25 PriviteraMD, HomanRW, Ludden™, PeckCC, VaskoMR1989Clinical utility of a bayesian dosing program for phenytoinTherapeutic Drug Monitoring 11 285 294
- 26 MurphyMG, PeckCC, MerensteinGB, RoddenD1990An evaluation of Bayesian microcomputer predictions of theophylline concentrations in newborn infantsTherapeutic Drug Monitoring 12 47 53
- 27 HudsonSA, FarquharDL, ThompsonD, SmithRG1990Phenytoin dosage individualization – five methods compared in the elderlyJournal of Clinical Pharmacy and Therapeutics 15 25 34
- 28 Vázquez RodríguezA, Santos BuelgaD, Alonso GonzálezAC, García SánchezMJ, Domínguez-Gil HurleA1991Comparison of methods for the prediction of phenytoin concentrationsJournal of Clinical Pharmacy and Therapeutics 16 55 62
- 29 El DesokyE, MeinshausenJ, BuhlK1993Generation of pharmacokinetic data during routine therapeutic drug monitoring: Bayesian approach vs. pharmacokinetic studies.Therapeutic Drug Monitoring 15 281 288
- 30 ScheyerRD, CramerJA, MattsonRH1994A pharmacodynamic approach to the estimate of carbamazepine autoinductionJournal of Pharmaceutical Sciences 83 491 494
- 31 GarciaMJ, GaviraR, Santos BuelgaD, Dominguez-GilA1994Predictive performance of two phenytoin pharmacokinetic dosing programs from non-steady-state dataTherapeutic Drug Monitoring 16 380 387
- 32 NakashimaE, MatsushitaR, KidoH, NakamuraM, AsahiM, IchimuraF1995Systematic approach to a dosage regimen for phenytoin based on the one-point, steady-state plasma concentrationTherapeutic Drug Monitoring 17 12 18
- 33 KodamaY, KuranariM, KodamaH, FujiiI, TakeyamaM1995Evaluation of equations for unbound serum concentration prediction of carbamazepine and carbamzepine-10,11-epoxide in polytherapy pediatric patients with epilepsyJournal of Pharmaceutical Sciences 84 835 839
- 34 RatnajaraN & HjelmM1995Prediction of free levels of phenytoin and carbamazepine in patients comedicated with valproic acidTherapeutic Drug Monitoring 17 327 332
- 35 GaulierJM, BoulieuR, FischerC, MauguiereF1997Prediction of carbamazepine concentrations using a Bayesian program (PKS System, Abbott): a retrospective evaluation in an outpatient populationJournal of Pharmacy and Pharmacology 49 734 736
- 36 ChanE1997Single-point phenytoin dosage prediction in Singapore ChineseJournal of Clinical Pharmacy and Therapeutics 22 47 52
- 37 ShorvonSD1990Epidemiology classification, natural history and genetic of epilepsyLancet 336 93 96
- 38 BrodieMJ & DichterMA1996Antiepileptic drugsThe New England Journal of Medicine 18 168 175
- 39 PughCB & GarnettWR1991Therapy review: current issues in the treatment of epilepsyClinical Pharmacy 10 335 358
- 40 ScheuerML & PedleyTA1990The evaluation and treatment of seizuresThe New England Journal of Medicine 323 1468 1474
- 41 KleijnE, SchobbenF, VreeTB1980Clinical pharmacokinetics of antiepileptic drugsDrug Intelligence Clinical Pharmacy 14 674 685
- 42 EichelbaumM, TomsonT, TybringG, BertilssonL1985Carbamazepine metabolism in man: induction and pharma- cogenetic aspectsClinical Pharmacokinetics 10 80 90
- 43 WestenbergHGM, KleijnE, OeiTT, ZeeuwRA1978Kinetic of carbamazepine and carbamazepine-epoxide, determined by use of plasma and salivaClinical Pharmacology and Therapeutics 23 320 328
- 44 YukawaE1995Population-based investigation of carbamazepine relative clearance using routine clinical pharmacokinetic data in Japan. A multiple peak approach feasibility study for pharmacokinetic screeningClinical Drug Investigation 10 29 39
- 45 MillerR & Ludden™1993Bioavailability of controlled release carbamazepine estimated by mixed effect modellingEuropean Journal of Clinical Pharmacology 44 231 235
- 46 WongYY, Ludden™, BellRD1983Effect of erythro?micin on carbamazepine kineticsClinical Pharmacology and Therapeutics 33 460 464
- 47 IsmailR & RahmanAFA1993Estimation of population pharmacokinetics for carbamazepine in Malaysian patients using the OPTQ computer programJournal of Clinical Pharmacy and Therapeutics 18 55 58